Anti-idiotype antibodies in cancer treatment

Frontiers in Oncology

Volumn 3 FEB, Issue , 2013, Pages

  Gomez, Daniel E ^a   Vázquez, Ana M ^b   Alonso, Daniel F ^a   Macías, Amparo ^b  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; RACOTUMOMAB; TUMOR ANTIGEN;

CANCER CHEMOTHERAPY; CANCER THERAPY; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOTHERAPY; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 84888322429     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00037     Document Type: Editorial

References (11)

1. Fredriksen, A. B., Sandlie, I., and Bogen, B. (2012). Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front. Oncol. 2:154. doi: 10.3389/fonc.2012.00154
2. Gomez, D. E., Vázquez, A. M., and Alonso, D. F. (2012). Cancer antigen prioritization: a road map to work in defining vaccines against specific targets. A point of view. Front. Oncol. 2:66. doi: 10.3389/fonc.2012.00066
3. Gómez, R. E., and Ardigo, M. L. (2012). Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective. Front. Oncol. 2:147. doi: 10.3389/fonc.2012.00147
4. Kieber-Emmons, T., Monzavi-Karbassi, B., Pashov, A., Saha, S., Murali, R., and Kohler, H. (2012). The promise of the anti-idiotype concept. Front. Oncol. 2:196. doi: 10.3389/fonc.2012.00196
5. Ladjemi, M. Z. (2012). Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements. Front. Oncol. 2:158. doi: 10.3389/fonc.2012.00158
6. Llanos, A., Savignano, M., and Cinat, G. (2012). Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report. Front. Oncol. 2:152. doi: 10.3389/fonc.2012.00152
7. López-Requena, A., Burrone, O. R., and Cesco-Gaspere, M. (2012). Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front. Oncol. 2:159. doi: 10.3389/fonc.2012.00159
8. Sampor, C., Guthmann, M. D., Scursoni, A., Cacciavillano, W., Torbidoni, A., Galluzzo, L., et al. (2012). Immune response to racotumomab in a child with relapsed neuroblastoma. Front. Oncol. 2:195. doi: 10.3389/fonc.2012.00195
9. Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., and Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front. Oncol. 2:160. doi: 10.3389/fonc.2012.00160
10. Vázquez, A. M., Hernández, A. M., Macías, A., Montero, E., Gómez, D. E., Alonso, D. F., et al. (2012a). Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides-preclinical and clinical data. Front. Oncol. 2:150. doi: 10.3389/fonc.2012.00150
11. Vázquez, A. M. H., Rodríguez-Zhurbenko, N., and López, A. M. V. (2012b). Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry. Front. Oncol. 2:170. doi: 10.3389/fonc.2012.00170